TB-500 Reconstitution Calculator
Turn a target dose you already have into the exact injection volume and insulin syringe units for your vial. It does the math only and never picks a dose for you.
Most people who search for a TB-500 dosage calculator want a tool that tells them what to inject. This calculator will not choose that number, and it cannot. There is no established human dose to fall back on. No regulator has approved TB-500, no label sets a figure, and no human efficacy trial of the injectable fragment has defined one. This tool handles the part that is pure arithmetic: once you already have a target dose from your own protocol or supplier, it converts that dose into a concentration, an injection volume in millilitres, and the units to draw on an insulin syringe.
Enter your own numbers
The target dose starts at zero and nothing is calculated until you set it yourself. TB-500 has no established human dose: no regulator has approved it and no label sets a figure. Drag the slider to whatever your protocol source specifies.
Target dose from your protocol or supplier. It starts at zero, so drag the slider to your own figure and the mg-to-mL math updates as you move it. The calculator never sets a dose for you and has no recommendation to make.
What the evidence and the community report
These are amounts recorded in published studies, trial registries, and named community sources, not recommendations. The Who column says whether a figure came from people, from animals, or from self-report, and the numbered Ref ties each row to the Sources list at the bottom of this page.
A. Approved label doses
None. No regulator has approved TB-500, and a DailyMed search returns zero records for it.
B. Amounts administered in published studies
Recorded as stated, and no row here used TB-500 itself except the rat study: the human rows used full-length or recombinant human thymosin beta-4.
Caution: none of these studies used subcutaneous injection, the route the syringe math above assumes.
| Amount | Schedule | Route | Who | Ref |
|---|---|---|---|---|
| 60 microgram/kg/day | daily for four weeks | intraperitoneal | rat, n=32 | [8] |
| 0.01 percent w/w, 0.03 percent w/w and 0.1 percent w/w gel | not stated | topical | human, n=72 | [9] |
| 0.25, 0.5 and 2.0 microgram/kg | 12 plus or minus 4 hours after PCI, then daily on day 2 to day 7 | IV injection | human, n=62 | [10] |
| 0.1 percent ophthalmic solution | for 28 days | topical ophthalmic | human, n=72 | [3] |
| 0.5 mg/ml gel | 4 week treatment | topical, scalp | human, n=71 plus 21 healthy | [11] |
| 42, 140, 420 or 1,260 mg | single dose per cohort, then the same dose daily for 14 days | intravenous | human, n=4 cohorts of 10 | [12] |
| single dose 0.05, 0.25, 0.5, 2.0, 5.0, 12.5 or 25.0 microgram/kg; multiple dose 0.5, 2.0 and 5.0 microgram/kg | single dose; multiple dose once daily for 10 days | intravenous | human, n=54 single dose, n=30 multiple dose | [13] |
C. Community reported practice
Self-reported, not peer reviewed, and the publisher has a commercial interest.
| Amount | Schedule | Route | Who | Ref |
|---|---|---|---|---|
| 2 to 2.5 mg (loading phase) | twice weekly for 4 to 6 weeks | subcutaneous or intramuscular | self-reported | [14] |
| 2 to 2.5 mg (maintenance phase) | once weekly or every two weeks | subcutaneous or intramuscular | self-reported | [14] |
Disclaimer: no figure here is a recommendation, animal per kilogram figures do not convert to a human dose, and this is education, not medical advice.
Two worked math examples
Both examples use 2.5 mg because it is a round number that keeps the division easy to follow on a 5 mg vial. It is not a recommendation. They illustrate arithmetic only and are not doses to take.
Example A: 5 mg vial with 2 mL
Illustrative arithmetic only, not a dose recommendation. The concentration is 5 / 2 = 2.5 mg/mL, or 2500 mcg/mL. A 2.5 mg target gives 2500 / 2500 = 1.0 mL, which is 100 units on a U-100 syringe. The vial contains 5000 / 2500 = 2 illustrative draws and the volume fits a 1.0 mL syringe.
Example B: 10 mg vial with 2 mL
Illustrative arithmetic only. The concentration is 10 / 2 = 5 mg/mL, or 5000 mcg/mL. The same 2.5 mg target gives 2500 / 5000 = 0.5 mL, which is 50 units on a U-100 syringe. The vial contains 10000 / 2500 = 4 illustrative draws and the volume fits a 0.5 mL syringe.
The 2.5 mg figure is a round number chosen only because it divides cleanly on a 5 mg vial and keeps the arithmetic easy to follow. It is not a suggested amount, and the figure you put in the calculator should come from your own protocol source.
What this calculator does, and what it will not do
A reconstitution calculator answers a mechanical question. You have a vial of freeze dried peptide and add a known volume of water. That fixes the concentration. From there, any target number you enter has one matching draw volume, and the calculator finds it. There is no judgment in that step, only division.
What it will not do is choose the dose. With TB-500 that line is a hard one for a specific reason: there is no established human dose to fall back on. No regulator has approved it, no label sets a figure, and no human efficacy trial of the injectable fragment has defined one. So the target dose is something you bring to the calculator, not something it gives you. If you do not have a number from a licensed prescriber or a protocol source you trust, no calculation on this page can supply one.
How to reconstitute a TB-500 vial
If your vial contains lyophilized powder, reconstitution means adding the water volume you entered above and letting the powder dissolve. These are general vial-handling steps, not instructions for choosing or administering a dose.
Wipe both rubber stoppers with an alcohol swab and let them dry, then draw the water volume you entered in the calculator into a syringe. Insert the needle at a slight angle so the water runs down the inside wall of the peptide vial instead of directly onto the powder.
Add the water slowly and do not shake the vial. Swirl gently until the solution is clear, label the vial with the date and calculated concentration in mg/mL, and follow the supplier's written storage and handling instructions.
Water choice and storage sit outside the calculator's arithmetic. For the difference between the two common water types, see bacteriostatic water vs sterile water. For a general mixing walkthrough, see how to use peptides.
Picking the BAC water volume
The amount of water you add does not change how much peptide is in the vial. It changes the concentration and therefore the liquid volume for the target number you enter. A 5 mg vial reconstituted with 1 mL is twice as concentrated as the same vial with 2 mL, so the draw is half the volume for the same target. More water spreads the syringe marks out, while less water concentrates the draw. The calculator recomputes instantly so you can compare volumes and use the written instructions that came with your vial.
Reading the insulin syringe
The calculator uses the U-100 conversion:
1 unit = 0.01 mL
100 units = 1 mL = full 1 mL barrel
A result of 0.5 mL is 50 units, and a result of 0.25 mL is 25 units. The calculator shows both formats so you can match the volume to a U-100 syringe. It also checks the result against the selected 0.3 mL, 0.5 mL, or 1.0 mL barrel capacity.
Why the calculator does not choose a dose
The human studies below used the full thymosin beta-4 peptide in topical or hospital IV forms. The other cited work is preclinical or review evidence, including a mouse study of a synthetic actin-binding fragment. This is not a gap in one reading list: there is no established human dose for TB-500 to fall back on anywhere. No regulator has approved it, no label sets a figure, and no human efficacy trial of the injectable fragment has defined one, so the calculator has no research-backed figure it can choose.
That evidence gap explains the boundary. This calculator stays with the reconstitution math. For information about the compound itself, read the TB-500 compound profile.
Sources
1. Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S. 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. 2022 Dec 29;24(1):. PMID: 36613994. DOI: 10.3390/ijms24010554.
2. Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015 May;34(5):491-6. PMID: 25826322. DOI: 10.1097/ICO.0000000000000379.
3. Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015;9:877-84. PMID: 26056426. DOI: 10.2147/OPTH.S80954.
4. Treadwell T, Kleinman HK, Crockford D, Hardy MA, Guarnera GT, Goldstein AL. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci. 2012 Oct;1270:37-44. PMID: 23050815. DOI: 10.1111/j.1749-6632.2012.06717.x.
5. Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003 Jan-Feb;11(1):19-24. PMID: 12581423. DOI: 10.1046/j.1524-475x.2003.11105.x.
6. Tan SH, Loo SJ, Gao Y, Tao ZH, Su LP, Wang CX, et al. Thymosin β4 increases cardiac cell proliferation, cell engraftment, and the reparative potency of human induced-pluripotent stem cell-derived cardiomyocytes in a porcine model of acute myocardial infarction. Theranostics. 2021;11(16):7879-7895. PMID: 34335970. DOI: 10.7150/thno.56757.
7. Zhang Y, Dong Q, Bian X, Qiao Z, Cui C, Yang N, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res. 2025 Dec 31;121(17):2747-2758. PMID: 41229390. DOI: 10.1093/cvr/cvaf223.
8. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026. PMID: 42542926. Studies TB-500 itself, as synthetic thymosin beta-4. Model: Sprague-Dawley rat, Achilles tendon transection and repair, 8 per group.
9. Dose-response study of thymosin beta 4 in venous stasis ulcers. Sponsor: RegeneRx Biopharmaceuticals. Status: COMPLETED. ClinicalTrials.gov: NCT00832091. Molecule: full-length thymosin beta-4, not TB-500. This is a gel concentration, not an injected amount. Population: patients with venous stasis ulcers, three groups of 18 active plus 6 placebo each.
10. Phase IIa study of injectable recombinant human thymosin beta 4 (NL005). Sponsor: Beijing Northland Biotech. Status: COMPLETED. ClinicalTrials.gov: NCT05485818. Molecule: recombinant full-length human thymosin beta-4, not TB-500. Population: patients with acute myocardial infarction after percutaneous coronary intervention, 62 enrolled per the record.
11. Recombinant human thymosin beta-4 (rhTbeta4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis. Microb Biotechnol. 2021. PMID: 34318587. Molecule: recombinant full-length human thymosin beta-4, not TB-500. Population: 71 patients with seborrheic dermatitis and 21 healthy individuals, compared against 2 percent ketoconazole lotion.
12. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. PMID: 20536472. Molecule: full-length synthetic thymosin beta-4, not TB-500. These are the largest human milligram amounts in this dataset. Population: healthy volunteers, 4 cohorts of 10 subjects each.
13. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 (NL005) in healthy Chinese volunteers. J Cell Mol Med. 2022. PMID: 34346165. Molecule: recombinant full-length human thymosin beta-4 (NL005), not TB-500. Population: healthy Chinese volunteers, 54 in the single dose trial across 7 cohorts, 30 in the multiple dose trial.
14. TB-500.COM. TB-500 Dosage: Complete Guide to Protocols, Dosing and Administration. https://tb500.org/dosage. Fetched 2026-08-04. Self-reported and not peer reviewed. Commercial interest: this publisher promotes physician supervised TB-500 therapy through its own telehealth and physician network. No per kilogram figures appear on this page. Population: self-selected community, not a study population.
Frequently asked questions
Is there a standard TB-500 dose I can put in this calculator?
No. There is no established human dose to fall back on. No regulator has approved TB-500, no label sets a figure, and no human efficacy trial of the injectable fragment has defined one. That is why the target dose starts at zero: there is no research-backed figure the calculator could put there. Whatever number you set has to come from your own prescriber or a protocol you trust. The tool does the math on it and nothing else.
How do I use this calculator for my own target dose?
The target dose starts at zero and the results stay hidden until you set it. Drag the dose slider to whatever figure your own protocol or supplier specifies, in mcg or mg, and the calculator recomputes the injection volume, insulin syringe units, and how many doses the vial holds. It does not judge the number you set. It only does the arithmetic on it.
How much BAC water do I add to a 5 mg TB-500 vial?
There is no single answer from the calculator because water volume is a readability choice, not a potency choice. A 5 mg vial in 2 mL of water gives a concentration of 2.5 mg/mL. The same vial in 1 mL gives 5 mg/mL, so whatever target you enter draws half the volume at the higher concentration. More water spreads the marks out on the syringe, less water concentrates the draw, and neither changes how much peptide is in the vial. For the same arithmetic without a compound preset, use the general peptide reconstitution calculator.
Why does this calculator not choose a target dose?
A reconstitution calculator can divide the peptide in a vial by the water added, but it cannot turn research into medical advice. TB-500 has no established human dose to fall back on: no regulator has approved it, no label sets a figure, and no human efficacy trial of the injectable fragment has defined one. You bring the target number, and the calculator handles only the concentration and draw math.
Why does changing BAC water change the syringe reading?
The amount of peptide in the vial stays fixed. Adding more water lowers the concentration, so the same target dose needs a larger draw volume. Adding less water raises the concentration, so the same target dose needs a smaller draw volume. The calculator updates both the millilitres and U-100 syringe units when you move the water slider.
How do I read insulin syringe units?
On a U-100 insulin syringe, 1 unit equals 0.01 mL and 100 units equals 1 mL. The calculator multiplies the injection volume in millilitres by 100 and shows the result as syringe units. Check that result against the markings and capacity of the syringe you selected.
Is this calculator medical advice?
No. It is harm reduction education. It performs reconstitution arithmetic on numbers you supply. It does not diagnose, prescribe, or tell you what dose to take. Always cross-check with your protocol source, supplier instructions, and where possible a qualified clinician.
This is harm reduction education, not medical advice
This calculator is for educational use. It converts a dose you already have into a volume and syringe reading. It does not choose a dose. Always cross-check with your protocol source, supplier instructions, and where possible a qualified clinician.